The foundational error in pharmaceutical valuation lies in conflating the statutory patent term with commercial exclusivity. Generalist investors and market
Forecast Pharma Revenue Without the Cliff Myth Read Post »
Big pharma used to treat loss of exclusivity as a weather event. You saw the date on the Gantt chart,
Steal Years Back From Your Patent Cliff Read Post »
The business model for off-patent medicine is undergoing a forced evolution. For four decades, the Hatch-Waxman Act provided a predictable
Secure the Future of Branded Generics Read Post »
The pharmaceutical sector operates on a punishing mathematical divide. In 2024, generic and biosimilar medicines filled 90% of all prescriptions
Sell Trust, Not Molecules: The 100% Premium Strategy Read Post »
The Convergence of Federal Exclusivity and Public Health Necessity The pharmaceutical industry operates on a fundamental tension between two opposing
Reclaiming Revenue in the Patent Cliff The pharmaceutical industry faces a contraction of unprecedented scale. Between 2025 and 2030, nearly
Sell More After Patents Die Read Post »
Pharmaceutical revenue is a melting ice cube. Between 2025 and 2030, the global industry faces a wave of patent expirations
The pharmaceutical industry is currently moving through the most concentrated period of exclusivity loss in its history. Between 2025 and
Win the Biosimilar War Read Post »
Introduction: From Herbal Roots to a Global Vanguard The history of the Japanese pharmaceutical industry presents a compelling and instructive
Sign in or create a free account to read this DrugPatentWatch article
